Marta Boffito
Chelsea and Westminster Hospital NHS Foundation Trust, London · Chelsea and Westminster NHS Foundation Trust · St Stephen's Clinical Research
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
33
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
64
PubMed author-name match
Trials
Studies that name Marta Boffito as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:49 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT04944654 · Efficacy, Tolerability and Acceptability of Biktarvy by TPLWHChelsea and Westminster NHS Foundation Trust · terminated · Human Immunodeficiency Virus · principal investigator
- Ph3NCT04892654 · Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy SwitchChelsea and Westminster NHS Foundation Trust · recruiting · HIV-1-infection · principal investigator
- Ph3NCT04653194 · Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'Chelsea and Westminster NHS Foundation Trust · completed · Human Immunodeficiency Virus · principal investigator
- N/ANCT03922269 · Trans People Living With HIV Throughout EuropeChelsea and Westminster NHS Foundation Trust · completed · HIV Infections, Gender Identity, Human Immunodeficiency Virus · principal investigator
- Ph1NCT03894124 · Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy VolunteersChelsea and Westminster NHS Foundation Trust · completed · Human Immunodeficiency Virus · principal investigator
- Ph1NCT03186482 · RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TPSt. Stephens Clinical Research · completed · HIV · principal investigator
- Ph1NCT03094507 · The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy VolunteersSt Stephens Aids Trust · completed · HIV · principal investigator
- Ph1NCT02832778 · Pharmacokinetics of Efavirenz in the Presence of Rifampicin and IsoniazidSt Stephens Aids Trust · unknown · HIV · principal investigator
- Ph1NCT02697851 · Pharmacokinetic Effect of Evotaz/Microgynon Co-administrationSt Stephens Aids Trust · terminated · HIV · principal investigator
- Ph1NCT02631473 · PK of Efavirenz & Lopinavir Nano-formulations in Healthy VolunteersSt Stephens Aids Trust · suspended · HIV · principal investigator
- Ph1NCT02589158 · SSAT067 PK of Atazanavir/Cobicistat and Darunavir/CobicistatSt Stephens Aids Trust · completed · HIV · principal investigator
- Ph4NCT02509195 · SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and OverSt Stephens Aids Trust · completed · HIV · principal investigator
- Ph1NCT02499874 · SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected WomenSt Stephens Aids Trust · completed · HIV · principal investigator
- N/ANCT02354209 · Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor TherapySt Stephens Aids Trust · unknown · HIV · principal investigator
- Ph1NCT01841593 · A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy VolunteersSt Stephens Aids Trust · completed · HIV · principal investigator
- Ph1NCT01663922 · Boceprevir and Ucalm (St John&Apos;s Wort)St Stephens Aids Trust · completed · Hepatitis C · principal investigator
- Ph4NCT01475227 · Atazanavir/Ritonavir and Zinc Pharmacokinetic StudySt Stephens Aids Trust · completed · HIV Infection · principal investigator
- Ph4NCT01335620 · The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of AgeImperial College London · completed · HIV · principal investigator
- N/ANCT01330342 · Evolution of Cellular and Viral Resistance in HIV-infected Patients With LymphomaSt Stephens Aids Trust · unknown · HIV, Lymphoma · principal investigator
- N/ANCT01286623 · The Pharmacology/Aging ClinicSt Stephens Aids Trust · completed · HIV Infection · principal investigator
- Ph1NCT01275443 · Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.St Stephens Aids Trust · completed · HIV Infection · principal investigator
- Ph3NCT01271894 · The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)Kirby Institute · completed · HIV Infection · principal investigator
- Ph1NCT01123915 · A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected PeopleMedicines Development for Global Health · terminated · HIV Infections · principal investigator
- Ph1NCT01108926 · PK of Tenofovir, Emtricitabine and Efavirenz in Healthy VolunteersSt Stephens Aids Trust · completed · HIV Infection, HIV Infections · principal investigator
- Ph1NCT01073761 · Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail StudySt Stephens Aids Trust · completed · HIV, HIV Infections · principal investigator
- Ph1NCT01071031 · HIV Vaccine Study in HIV Positive PatientsPepTcell Limited · completed · HIV Infections · principal investigator
- Ph1/Ph2NCT01049932 · Pre-Exposure Prophylaxis Using TMC278LASt Stephens Aids Trust · terminated · HIV Infections · principal investigator
- Ph1NCT01047995 · Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected SubjectsSt Stephens Aids Trust · completed · HIV Infections · principal investigator
- Ph1NCT00985543 · Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.Kirby Institute · completed · Acquired Immunodeficiency Syndrome · principal investigator
- Ph1/Ph2NCT00985647 · Pharmacokinetics of Lamivudine at Two Different DosesKirby Institute · completed · HIV Infections · principal investigator
- Ph1NCT00772551 · Raltegravir and Ezetimibe PK StudySt Stephens Aids Trust · completed · HIV · principal investigator
- Ph1NCT00765271 · Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected SubjectsSt Stephens Aids Trust · completed · HIV · principal investigator
- Ph1NCT00531323 · TMC 125 Blood Levels StudySt Stephens Aids Trust · completed · HIV Infections · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:49 UTC. The ranking covers the 200 most relevant of 64 PubMed records, and a shared surname and initials can bring in a namesake. All 64 on PubMed
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.N Engl J Med · 2021870 citationsRCR 47.3
- A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.Clin Pharmacol Ther · 201492 citationsRCR 2.9
- 70 citationsRCR 2.0
- Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Clin Pharmacol Ther · 201567 citationsRCR 2.9
- Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.Clin Infect Dis · 200965 citationsRCR 1.5
- Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.Clin Infect Dis · 202354 citationsRCR 3.8
- Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.J Antimicrob Chemother · 201953 citationsRCR 2.7
- 50 citationsRCR 1.3
- Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.Lancet Infect Dis · 202350 citationsRCR 2.7
- Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.Antimicrob Agents Chemother · 200946 citationsRCR 1.4